- Hypertrophic Cardiomyopathy (HCM)
- Vaccines: 2023 Year in Review
- Eyecare
- Urothelial Carcinoma
- Women's Health
- Hemophilia
- Heart Failure
- Vaccines
- Neonatal Care
- NSCLC
- Type II Inflammation
- Substance Use Disorder
- Gene Therapy
- Lung Cancer
- Spinal Muscular Atrophy
- HIV
- Post-Acute Care
- Liver Disease
- Pulmonary Arterial Hypertension
- Biologics
- Asthma
- Atrial Fibrillation
- Type I Diabetes
- RSV
- COVID-19
- Cardiovascular Diseases
- Breast Cancer
- Prescription Digital Therapeutics
- Reproductive Health
- The Improving Patient Access Podcast
- Blood Cancer
- Ulcerative Colitis
- Respiratory Conditions
- Multiple Sclerosis
- Digital Health
- Population Health
- Sleep Disorders
- Biosimilars
- Plaque Psoriasis
- Leukemia and Lymphoma
- Oncology
- Pediatrics
- Urology
- Obstetrics-Gynecology & Women's Health
- Opioids
- Solid Tumors
- Autoimmune Diseases
- Dermatology
- Diabetes
- Mental Health
Florida’s Medicaid Program Puts Pear PDTs on Its Preferred Drug List
Pear also recently announced a deal with California's Medicaid program that involves supporting a pilot project to help people with stimulant use disorder.
Pear Therapeutics announced today that its reSET and reSET-O prescription digital therapeutics have been added to Florida’s Medicaid preferred drug list.
“Pear applauds Florida leadership for bringing reSET and reSET-O to its millions of Medicaid members in its persistent efforts to tackle the addiction crisis and bring innovative treatment options to those seeking recovery,” Julia Strandberg, MBA, Chief Commercial Officer of Pear Therapeutics.
The announcement about inclusion on Florida’s Medicaid preferred drug lists comes on the heels of a company announcement about a California Medicaid pilot program for treatment of stimulant use disorder that involves use of Pear’s services.
Related:California Medi-Cal Contracts With Pear to Treat Stimulant Use Disorder
ReSET is used as a monotherapy for patients 18 years of age or older with substance use disorder related to alcohol, cannabis, cocaine, and methamphetamine. ReSET-O is used in combination with buprenorphine-based medication- assisted treatment for patients 18 years of age or older with opioid use disorder.
According to Pear, the Florida Medicaid program has an enrollment of approximately five million, the third highest in the country.
FDA Expands Akili's EndeavorRx Game-Based Digital Therapy for ADHD Eligibility to Ages 8-17
December 21st 2023As the only FDA-approved, game-based digital therapeutic, EndeavorRx’s eligibility is expected to more than double the number of pediatric patients with ADHD who have a prescription from a healthcare provider, due to the increased age range.
Read More
